• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

A single glucocorticoid injection provides only short-term relief from chronic low back pain

byCaitlyn HuiandDeepti Shroff Karhade
March 28, 2017
in Chronic Disease
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Single glucocorticoid injections provided symptomatic relief from chronic low back pain after one month.

2. No differences in low back pain were observed between patients and controls after 12 months.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Chronic low back pain (LBP) is known to cause long-term disability. One subtype of chronic LBP is active discopathy, where local inflammation contributes to patient symptoms. Based on this pathophysiology, current treatments being investigated for active discopathy include drugs that target local inflammation. As a result, the authors of this study aimed to assess the efficacy of a single glucocorticoid intradiscal injection (GC IDI) as treatment for such patients. In general, they observed that a single GC IDI reduces LBP only in the short-term. This study has several limitations. First, patients were recruited from tertiary care centers and may not be representative of the general population with active discopathy. Additionally, the dose regimen and properties of the glucocorticoid may have impacted the results of the study—the authors suggested that a dose-optimization schedule or less soluble glucocorticoid might be needed to optimize results. Overall, this trial suggests that GC IDI may have positive effects on patients in the short-term; however, the treatment efficacy is uncertain due to its insignificant long-term benefits.

Click to read the study in the Annals of Internal Medicine

Relevant Reading: The Affordable Care Act, Five Years Later: Policies, Progress, and Politics

In-Depth [randomized controlled trial]: The authors conducted a prospective, parallel-group, double-blind, randomized, controlled, multicenter study. Patients included in this study had daily LBP for at least 3 months, with mean intensity greater than 40 when ranked from 0 (no pain) to 100 (maximum pain). Patients were then randomly assigned to either the treatment or control group. The authors observed significant results in symptom relief at 1 month following GC IDI. For example, the percentage of responders (LBP intensity < 40) was higher in the treatment group (36 of 65 [55.4%]) than the control group (21 or 63 [33.3%]) (absolute risk difference 22.1 percentage points, 95%CI 5.5 to 38.7 percentage points, p = 0.009). In contrast, no significant difference in response was observed at 12 months, both in LBP intensity and in most secondary outcomes. These results suggest that GC IDI may not be an effective treatment for active discopathy in the long-term.

RELATED REPORTS

Changes in opioid or nonopioid pain treatments not attributable to state opioid prescribing laws

#VisualAbstract: Therapeutic aquatic exercise is superior at improving disability and severity of low back pain compared to physical therapy

Therapeutic aquatic exercise is superior at improving disability and severity of low back pain compared to physical therapy

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: back paincorticosteroids
Previous Post

Multiple oral direct-acting antiviral regimens associated with sustained virologic response for hepatitis C virus infection

Next Post

A virtual glucose management service significantly improved glycemic control in hospitalized patients

RelatedReports

Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use
Chronic Disease

Changes in opioid or nonopioid pain treatments not attributable to state opioid prescribing laws

March 30, 2022
#VisualAbstract: Therapeutic aquatic exercise is superior at improving disability and severity of low back pain compared to physical therapy
StudyGraphics

#VisualAbstract: Therapeutic aquatic exercise is superior at improving disability and severity of low back pain compared to physical therapy

January 19, 2022
Exercise improves aromatase inhibitor-induced arthralgia in breast cancer survivors
Chronic Disease

Therapeutic aquatic exercise is superior at improving disability and severity of low back pain compared to physical therapy

January 14, 2022
#VisualAbstract: Addition of itacitinib to corticosteroids did not show clinical benefit over placebo in initial treatment of acute graft-versus-host disease
StudyGraphics

#VisualAbstract: Addition of itacitinib to corticosteroids did not show clinical benefit over placebo in initial treatment of acute graft-versus-host disease

January 6, 2022
Next Post
Intrapartum serum prolactin may predict risk of postpartum diabetes

A virtual glucose management service significantly improved glycemic control in hospitalized patients

American Academy of Pediatrics recommends standards for adverse event disclosures

Dietary supplementation with vitamin D and calcium not associated with reduced cancer risk in older women

Molecular testing for Clostridium difficile may not predict disease activity

Recurrent Clostridium difficile infection associated with gastric acid suppression

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Stereotactic body radiotherapy as a state of the art treatment option in inoperable non-small cell lung cancer [Classics Series]
  • Health system-based care associated with better treatment use and high rates of tobacco abstinence at 3 months post-discharge in hospitalized smokers
  • APOEε4 genotype may increase risk of chronic traumatic encephalopathy following repetitive head impact
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.